Top 5 Stocks to Buy Now
→ Buy this stock today (From Chaikin Analytics) (Ad)tc pixel Free VINC Stock Alerts

Vincerx Pharma (VINC) Competitors

Vincerx Pharma logo
$0.01 0.00 (0.00%)
As of 10:23 AM Eastern
Compare

VINC vs. PTPI, AMPE, ARDS, SCPS, and VRPX

Should you buy Vincerx Pharma stock or one of its competitors? MarketBeat compares Vincerx Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vincerx Pharma include Petros Pharmaceuticals (PTPI), Ampio Pharmaceuticals (AMPE), Aridis Pharmaceuticals (ARDS), Scopus BioPharma (SCPS), and Virpax Pharmaceuticals (VRPX). These companies are all part of the "pharmaceutical products" industry.

How does Vincerx Pharma compare to Petros Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Petros Pharmaceuticals' return on equity of -78.22% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Petros PharmaceuticalsN/A -78.22% -23.50%
Vincerx Pharma N/A -248.33%-132.73%

Petros Pharmaceuticals has higher revenue and earnings than Vincerx Pharma. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Petros Pharmaceuticals$5.11M0.04-$8.16M-$1.64N/A
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A

In the previous week, Petros Pharmaceuticals had 2 more articles in the media than Vincerx Pharma. MarketBeat recorded 2 mentions for Petros Pharmaceuticals and 0 mentions for Vincerx Pharma. Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company Overall Sentiment
Petros Pharmaceuticals Neutral
Vincerx Pharma Neutral

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 8.2% of Petros Pharmaceuticals shares are held by insiders. Comparatively, 15.6% of Vincerx Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Petros Pharmaceuticals has a beta of 1.87, meaning that its stock price is 87% more volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

Summary

Petros Pharmaceuticals beats Vincerx Pharma on 7 of the 10 factors compared between the two stocks.

How does Vincerx Pharma compare to Ampio Pharmaceuticals?

Ampio Pharmaceuticals (NYSE:AMPE) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company Overall Sentiment
Ampio Pharmaceuticals Neutral
Vincerx Pharma Neutral

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Ampio Pharmaceuticals has a beta of 5.96, suggesting that its stock price is 496% more volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

Ampio Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Ampio PharmaceuticalsN/A N/A N/A
Vincerx Pharma N/A -248.33%-132.73%

Summary

Ampio Pharmaceuticals and Vincerx Pharma tied by winning 4 of the 8 factors compared between the two stocks.

How does Vincerx Pharma compare to Aridis Pharmaceuticals?

Vincerx Pharma (NASDAQ:VINC) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

Vincerx Pharma has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 45.1, indicating that its stock price is 4,410% more volatile than the broader market.

Vincerx Pharma is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.00

Aridis Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Vincerx PharmaN/A -248.33% -132.73%
Aridis Pharmaceuticals N/A N/A N/A

44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Vincerx Pharma Neutral
Aridis Pharmaceuticals Neutral

Summary

Aridis Pharmaceuticals beats Vincerx Pharma on 6 of the 8 factors compared between the two stocks.

How does Vincerx Pharma compare to Scopus BioPharma?

Vincerx Pharma (NASDAQ:VINC) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

Vincerx Pharma has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.14, meaning that its share price is 114% less volatile than the broader market.

Scopus BioPharma's return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Vincerx PharmaN/A -248.33% -132.73%
Scopus BioPharma N/A N/A N/A

In the previous week, Scopus BioPharma had 1 more articles in the media than Vincerx Pharma. MarketBeat recorded 1 mentions for Scopus BioPharma and 0 mentions for Vincerx Pharma. Scopus BioPharma's average media sentiment score of 0.99 beat Vincerx Pharma's score of 0.00 indicating that Scopus BioPharma is being referred to more favorably in the news media.

Company Overall Sentiment
Vincerx Pharma Neutral
Scopus BioPharma Positive

44.0% of Vincerx Pharma shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Scopus BioPharma beats Vincerx Pharma on 5 of the 8 factors compared between the two stocks.

How does Vincerx Pharma compare to Virpax Pharmaceuticals?

Vincerx Pharma (NASDAQ:VINC) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Vincerx Pharma has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Virpax Pharmaceuticals has a beta of 2.28, meaning that its share price is 128% more volatile than the broader market.

Vincerx Pharma is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A

Vincerx Pharma's return on equity of -248.33% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Vincerx PharmaN/A -248.33% -132.73%
Virpax Pharmaceuticals N/A -1,554.34%-338.29%

44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by company insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Vincerx Pharma Neutral
Virpax Pharmaceuticals Neutral

Summary

Vincerx Pharma beats Virpax Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Get Vincerx Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VINC vs. The Competition

Export
MetricVincerx PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$66K$981.91M$6.80B$12.17B
Dividend YieldN/A4.84%2.68%5.90%
P/E Ratio0.001.5025.7924.20
Price / SalesN/A129.09550.5894.97
Price / CashN/A20.0646.3353.91
Price / Book0.008.0110.776.37
Net Income-$40.16M-$4.05M$3.57B$337.69M
7 Day PerformanceN/A0.57%3.15%-0.30%
1 Month PerformanceN/A1.27%2.34%0.36%
1 Year PerformanceN/A47.36%33.42%26.94%

Vincerx Pharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VINC
Vincerx Pharma
N/A$0.01
flat		N/A-74.4%$66KN/AN/A60
PTPI
Petros Pharmaceuticals
N/A$0.01
+23.3%		N/A-81.3%$231K$5.11MN/A20
AMPE
Ampio Pharmaceuticals
N/A$0.18
flat		N/AN/A$208KN/AN/A20
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/A+300.0%$128KN/A0.0330
SCPS
Scopus BioPharma
N/A$0.00
flat		N/A+100.0%$17KN/AN/A9

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VINC) was last updated on 6/26/2026 by MarketBeat.com Staff.
From Our Partners
Problems at SpaceX: time to get out?
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Solar is dead. Here’s what replaces it.
Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-car...
Behind the Markets | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Gold Will Hit $4,900
JPMorgan now sees gold hitting $4,900, and central banks are buying at a record 710 tonnes per quarter. Trump'...
Investors Alley | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel